Sokolova, Elena
Oerlemans, Anoek M.
Rommelse, Nanda N.
Groot, Perry
Hartman, Catharina A.
Glennon, Jeffrey C.
Claassen, Tom
Heskes, Tom
Buitelaar, Jan K.
Funding for this research was provided by:
Seventh Framework Programme (278948 (TACTICS))
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (MoCoCaDi (612.001.202), 91610024)
National Institute of Mental Health (R01 MH62873-01A1)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (1750102007010)
European Community’s Horizon 2020 Program (43051 (MiND))
Innovative Medicines Initiative Joint Undertaking (115300 (EU-AIMS))
European Federation of Pharmaceutical Industries and Associations
Article History
First Online: 2 March 2017
Compliance with Ethical Standards
:
: Jan K. Buitelaar has been in the past 3 years a consultant to / member of advisory board of / and/or speaker for Janssen Cilag BV, Eli Lilly, Shire, Lundbeck, Medice and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. All other authors report no biomedical financial interests or potential conflicts of interest.
: The study was approved by the local medical ethics board and parents and children (12 years and older) signed for informed consent.